169 related articles for article (PubMed ID: 7252329)
21. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against *OH-mediated strand breaks.
Hermes-Lima M; Nagy E; Ponka P; Schulman HM
Free Radic Biol Med; 1998 Nov; 25(8):875-80. PubMed ID: 9840731
[TBL] [Abstract][Full Text] [Related]
22. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
Richardson DR
Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
[TBL] [Abstract][Full Text] [Related]
23. A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe.
Huang AR; Ponka P
Biochim Biophys Acta; 1983 Jun; 757(3):306-15. PubMed ID: 6849979
[TBL] [Abstract][Full Text] [Related]
24. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
25. Pyridoxal isonicotinoyl hydrazone and its analogues.
Buss JL; Hermes-Lima M; Ponka P
Adv Exp Med Biol; 2002; 509():205-29. PubMed ID: 12572996
[No Abstract] [Full Text] [Related]
26. Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration.
Brittenham GM
Ann N Y Acad Sci; 1990; 612():315-26. PubMed ID: 2291560
[No Abstract] [Full Text] [Related]
27. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone.
Hoy T; Humphrys J; Jacobs A; Williams A; Ponka P
Br J Haematol; 1979 Nov; 43(3):443-9. PubMed ID: 497121
[TBL] [Abstract][Full Text] [Related]
28. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
29. Pyridoxal isonicotinoyl hydrazone inhibits iron-induced ascorbate oxidation and ascorbyl radical formation.
MaurÃcio AQ; Lopes GK; Gomes CS; Oliveira RG; Alonso A; Hermes-Lima M
Biochim Biophys Acta; 2003 Mar; 1620(1-3):15-24. PubMed ID: 12595068
[TBL] [Abstract][Full Text] [Related]
30. Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation.
Hermes-Lima M; Gonçalves MS; Andrade RG
Mol Cell Biochem; 2001 Dec; 228(1-2):73-82. PubMed ID: 11855743
[TBL] [Abstract][Full Text] [Related]
31. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes.
Buss JL; Arduini E; Ponka P
Biochem Pharmacol; 2002 Dec; 64(12):1689-701. PubMed ID: 12445858
[TBL] [Abstract][Full Text] [Related]
32. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone.
Ponka P; Grady RW; Wilczynska A; Schulman HM
Biochim Biophys Acta; 1984 Dec; 802(3):477-89. PubMed ID: 6509088
[TBL] [Abstract][Full Text] [Related]
33. Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.
Richardson DR; Ponka P
J Lab Clin Med; 1998 Oct; 132(4):351-2. PubMed ID: 9794707
[No Abstract] [Full Text] [Related]
34. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro: reappraisal of reported partition coefficients.
Edward JT; Chubb FL; Sangster J
Can J Physiol Pharmacol; 1997 Dec; 75(12):1362-8. PubMed ID: 9534947
[TBL] [Abstract][Full Text] [Related]
35. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II).
Richardson DR; Hefter GT; May PM; Webb J; Baker E
Biol Met; 1989; 2(3):161-7. PubMed ID: 2490071
[TBL] [Abstract][Full Text] [Related]
36. The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron.
Chen YL; Kong X; Xie Y; Hider RC
J Inorg Biochem; 2018 Mar; 180():194-203. PubMed ID: 29329026
[TBL] [Abstract][Full Text] [Related]
37. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
38. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate.
Hermes-Lima M; Ponka P; Schulman HM
Biochim Biophys Acta; 2000 Oct; 1523(2-3):154-60. PubMed ID: 11042379
[TBL] [Abstract][Full Text] [Related]
39. Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs.
Buss JL; Neuzil J; Ponka P
Arch Biochem Biophys; 2004 Jan; 421(1):1-9. PubMed ID: 14678779
[TBL] [Abstract][Full Text] [Related]
40. Replacement of transferrin in serum-free cultures of mitogen-stimulated mouse lymphocytes by a lipophilic iron chelator.
Brock JH; Stevenson J
Immunol Lett; 1987 May; 15(1):23-5. PubMed ID: 3610230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]